Business Wire

Record-breaking Wearables Brand MyKronoz Gently Ribs Traditional Watchmakers in New Campaign

Del

Intentionally timed to coincide with the world’s biggest show for watches and jewelry, Baselworld 2018, premier watchmaker for the smart generation MyKronoz, has launched a digital campaign that goes beyond category clichés, and pokes fun at old-school watches and their wearers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180327005607/en/

MyKronoz newest video campaign: I'm a watch / I'm a smartwatch (Photo: MyKronoz)

MyKronoz newest video campaign: I'm a watch / I'm a smartwatch (Photo: MyKronoz)

Playfully contrasting the legacy-focused world in which owners of classic timepieces live with that of today’s connected generation, MyKronoz subtly introduces viewers to its groundbreaking hybrid smartwatch ZeTime – an affordable timepiece for traditional watch lovers who also want a smart device.

Debuting on social platforms, six spots in the ‘I’m a watch, I’m a smartwatch’ campaign portray two rival, quirky characters who respectively personify the watch and the smartwatch, and hint at the superiority of a hybrid device like ZeTime, which combines the best of two worlds.

In one spot we see classic watch man sitting meekly with an hourglass on his all but empty desk. By contrast, smartwatch man next to him is busy mixing the decks, taking phone calls, checking the weather and reviewing a map. "What (kind of work) do you do?" he asks, looking over at his unremarkable neighbour.

"Well, I tell the time…." .

"Nice!" replies smartwatch man, charitably.

Sarah Brault, MyKronoz CMO commented, “At a time when the watch market is facing key challenges and most wearable makers are not attending Baselworld 2018, we at MyKronoz are consciously bucking the trend and investing. This campaign is testament to our belief that great design, essential features, affordable prices and a creative approach to our marketing is what will set us apart from the rest.”

In its first five days the spots have been viewed over 2 million times on Facebook and Instagram.

MyKronoz recently broke crowdfunding records, raising over $8,000,000 for ZeTime in a year. This makes ZeTime the most crowd-funded hardware product of 2017, the highest funded hybrid smartwatch ever and MyKronoz the most funded European company in Kickstarter history.

ZeTime belongs to the fast-growing segment of hybrid smartwatches – a subcategory that will make up over 50% of the smartwatches market by 2022. Nearly 80 million hybrid smartwatches will be shipped by 2022, up 460% from an estimated 14 million in 2017 according to IDC. (These figures contrast with shipments of traditional Swiss watches, which decreased by 4.3% in 2017).

About ZeTime: The world's first hybrid smartwatch with mechanical hands over a color touchscreen, ZeTime offers the classic design of a Swiss timepiece with most advanced features of a smartwatch. MyKronoz’s proprietary ‘Smart Movement’ technology enables ZeTime’s always-on hands to function for up to 30 days with a single charge, ensuring the primary function of the watch – to tell time – is always running. With a retail price starting at $199, the hybrid device is available in two different case sizes (39mm and 44mm) and displays (1.05 inch and 1.22-inch). ZeTime boasts three collections comprising a variety of watch case finishing and bands, to appeal to a wide audience.

About MyKronoz: Founded in January 2013, MyKronoz is a Swiss company headquartered in Geneva that designs and develops wearable devices to expand and facilitate the connected experience of the smart generation. Bringing together the essence of watchmaking tradition with innovative technology, MyKronoz offers a full range of affordable and stylish wearables, starting at a price point of $39 only, spanning across 4 product categories: activity trackers, smartwatches, hybrid smartwatches and watch phones, all compatible with iOS and Android.

Present in more than 40 countries, carried by major retailers and partners worldwide (Orange, Auchan, Carrefour, Amazon, Best Buy...), MyKronoz has sold more than 3 million products and established itself as a fierce challenger to both tech and traditional watchmakers.

MyKronoz is part of BOW Group, a global player in the Internet of Things (IoT), operating worldwide in the wearables, connected vehicles and smart home markets. In July 2015, BOW raised €10 million from NextStage AM in series A funding round and closed in November 2017 its $23.5 million series B funding lead by PM Equity Partner, the corporate venture fund of Philip Morris International.

Creative credits: The « I’m a watch; I’m a smartwatch » campaign was co-created with YZ, a creative digital marketing agency based in Paris, Berlin and soon London. YZ is a protean, internationally focused team that mixes creativity, a design-thinking approach to idea generation and brand reputation management expertise.

Contact information

MyKronoz
Media:
Annabel Corlay
press@mykronoz.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

New Phase 3 data demonstrate superiority of TREMFYA®▼ (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 4817.12.2018 12:56Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the ECLIPSE study demonstrating that TREMFYA® (guselkumab) was superior to Cosentyx® (secukinumab)* in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at week 48. Data from the multicentre, randomised, double-blind head-to-head Phase 3 study demonstrated that 84.5 percent of patients treated with guselkumab achieved at least 90 percent improvement in their baseline Psoriasis Area Severity Index (PASI) score at week 48, compared with 70.0 percent of patients treated with secukinumab (p<0.001).1 These data, presented at the 3rd Inflammatory Skin Disease Summit (ISDS) in Vienna, 12–15 December, mark the first-ever results from a head-to-head study comparing an interleukin (IL)-23-targeted biologic therapy (guselkumab) with an IL-17 inhibitor (secukinumab). ECLIPSE is Janssen’s fourth Phase 3 study for guselkumab in plaque psoriasis2-4 and is part of a comprehen

Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients17.12.2018 12:30Pressemelding

Celgene Corporation (NASDAQ:CELG) today announced ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support cancer healthcare capacity building in resource-constrained countries around the world. The programs selected are expected to support established institutions partnering with in-country medical centers that provide essential cancer care services including awareness and education, prevention, diagnosis and care. The Celgene Cancer Care Links program is an initiative of Celgene Global Health, which focuses on healthcare challenges facing patients in developing parts of the world. “Celgene Cancer Care Links is another program we have created to make a meaningful impact for patients and healthcare systems around the world,” said Mark J. Alles, Chairman and Chief Executive Officer of Celgene. “We are excited to announce the first round of grants through this initiative and wish these world-renowned organizations and institutions

Ras Al Khaimah Marks New Year’s Eve with Amazing Fireworks and New Guinness World Record Bid17.12.2018 11:14Pressemelding

This New Year’s Eve, Ras Al Khaimah is the place to be as the Emirate readies to host the most spectacular celebration with a 12-minute fireworks display - the bid for a new Guinness World Record display - and an array of family-oriented activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005309/en/ Marjan, Ras Al Khaimah’s master-developer of freehold projects, will manage the show to mark 2019 with a glittering array of activities that will entertain all at its flagship development, Al Marjan Island. With three additional viewing areas around Al Marjan Island, New Year’s Eve in Ras Al Khaimah has fun and thrills in store for local and international visitors. Abdulla Al Abdouli, Managing Director & CEO of Marjan, said: “This year, we are offering exciting family activities that will delight all in the run-up to the amazing fireworks display that aims to set a new Guinness World Record. The event will position t

Mobidiag Announces Joint Venture with Autobio Diagnostics and €10m Equity Investment17.12.2018 09:52Pressemelding

Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, today announces that it has entered into a joint venture (‘JV’) agreement with Autobio Diagnostics (‘Autobio’), one of the leading clinical diagnostics companies in China, to commercialise the Novodiag® platform in China. In addition, Mobidiag announces that it has secured a separate €10m equity investment from Autobio. Lynx Financial (HK) Ltd, served as the exclusive financial advisor to Mobidiag in this transaction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005272/en/ Mobidiag and Autobio will jointly invest €12.3m to establish a joint venture company in China. Autobio will invest €8m in cash to hold 65%, and Mobidiag will invest €4.3m to hold 35%. Mobidiag will grant to the JV an exclusive license for human infectious disease assays (except for sepsis) for China. Initial activities of the JV will i

Prima Solutions and Effisoft Announce Their Merger to Bolster Global Leadership in Providing Insurance Solutions17.12.2018 09:00Pressemelding

As part of their continuing growth strategies, Prima Solutions and Effisoft announce their merger to create a global InsureTech company. This merger between Effisoft, the leading vendor of reinsurance and regulatory software solutions for insurance and reinsurance companies across the globe, and Prima Solutions, one of Europe’s leading software provider for Life, Health, and P&C insurance companies, will produce one of the largest and most comprehensive players in Europe, North America, and the Asia-Pacific region with cloud-based solutions covering all areas of the insurance market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005249/en/ This merger, concluded on December 13, will enable both groups to accelerate their development in the P&C, health and personal protection insurance markets. This merger is part of an ambitious and coherent growth strategy: it completes Prima Solutions' and Effisoft's existing produc

Algorand Appoints Pablo Azar as Chief Economist17.12.2018 09:00Pressemelding

Algorand, a foundational blockchain and cryptocurrency company, announced today that it has named Pablo Azar as Chief Economist. Given Algorand's focus on creating sustainable value in a decentralized economy, Mr. Azar will be responsible for guiding Algorand’s economic policies. On the heels of announcing Steve Kokinos and W. Sean Ford as CEO and COO, respectively, Mr. Azar’s appointment as Chief Economist is another advancement for Algorand as it continues to develop its executive team. With a double Ph.D. from MIT, Mr. Azar will bring his unique expertise regarding the application of computer science and cryptography toward the creation of better market mechanisms. Further, he will be responsible for expanding the visibility of Algorand’s economic policy and enhancing the tools necessary for developers to build on the Algorand platform. “As momentum around tokenization increases, so does the need for sound economic management,” said Steve Kokinos, CEO at Algorand. “With his deep bac